BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12061876)

  • 1. From imidazoles to pyrimidines: new inhibitors of cytokine release.
    Laufer SA; Wagner GK
    J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
    Laufer SA; Striegel HG; Wagner GK
    J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
    Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
    J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
    Laufer SA; Zimmermann W; Ruff KJ
    J Med Chem; 2004 Dec; 47(25):6311-25. PubMed ID: 15566301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imidazopyrimidines, potent inhibitors of p38 MAP kinase.
    Rupert KC; Henry JR; Dodd JH; Wadsworth SA; Cavender DE; Olini GC; Fahmy B; Siekierka JJ
    Bioorg Med Chem Lett; 2003 Feb; 13(3):347-50. PubMed ID: 12565927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
    Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
    J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An algorithm-directed two-component library synthesized via solid-phase methodology yielding potent and orally bioavailable p38 MAP kinase inhibitors.
    McKenna JM; Halley F; Souness JE; McLay IM; Pickett SD; Collis AJ; Page K; Ahmed I
    J Med Chem; 2002 May; 45(11):2173-84. PubMed ID: 12014955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, evaluation and docking of novel pyrazolo pyrimidines as potent p38α MAP kinase inhibitors with improved anti-inflammatory, ulcerogenic and TNF-α inhibitory properties.
    Somakala K; Tariq S; Amir M
    Bioorg Chem; 2019 Jun; 87():550-559. PubMed ID: 30928877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An in-vitro screening assay for the detection of inhibitors of proinflammatory cytokine synthesis: a useful tool for the development of new antiarthritic and disease modifying drugs.
    Laufer S; Greim C; Bertsche T
    Osteoarthritis Cartilage; 2002 Dec; 10(12):961-7. PubMed ID: 12464556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence.
    Underwood DC; Osborn RR; Kotzer CJ; Adams JL; Lee JC; Webb EF; Carpenter DC; Bochnowicz S; Thomas HC; Hay DW; Griswold DE
    J Pharmacol Exp Ther; 2000 Apr; 293(1):281-8. PubMed ID: 10734180
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-inflammatory effect and selectivity profile of AS1940477, a novel and potent p38 mitogen-activated protein kinase inhibitor.
    Terajima M; Inoue T; Magari K; Yamazaki H; Higashi Y; Mizuhara H
    Eur J Pharmacol; 2013 Jan; 698(1-3):455-62. PubMed ID: 23183108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.
    Wadsworth SA; Cavender DE; Beers SA; Lalan P; Schafer PH; Malloy EA; Wu W; Fahmy B; Olini GC; Davis JE; Pellegrino-Gensey JL; Wachter MP; Siekierka JJ
    J Pharmacol Exp Ther; 1999 Nov; 291(2):680-7. PubMed ID: 10525088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity.
    Adams JL; Boehm JC; Gallagher TF; Kassis S; Webb EF; Hall R; Sorenson M; Garigipati R; Griswold DE; Lee JC
    Bioorg Med Chem Lett; 2001 Nov; 11(21):2867-70. PubMed ID: 11597418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
    Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
    J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of MAP kinase pathways in mediating IL-6 production in human primary mesangial and proximal tubular cells.
    Leonard M; Ryan MP; Watson AJ; Schramek H; Healy E
    Kidney Int; 1999 Oct; 56(4):1366-77. PubMed ID: 10504489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chiral sulfoxides as metabolites of 2-thioimidazole-based p38α mitogen-activated protein kinase inhibitors: enantioselective synthesis and biological evaluation.
    Bühler S; Goettert M; Schollmeyer D; Albrecht W; Laufer SA
    J Med Chem; 2011 May; 54(9):3283-97. PubMed ID: 21449619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.
    Almansa C; de Arriba AF; Cavalcanti FL; Gómez LA; Miralles A; Merlos M; García-Rafanell J; Forn J
    J Med Chem; 2001 Feb; 44(3):350-61. PubMed ID: 11462976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MAP kinase inhibitors, PD098059, UO126 and SB203580, inhibit IL-1beta-dependent PGE(2) release via mechanistically distinct processes.
    Newton R; Cambridge L; Hart LA; Stevens DA; Lindsay MA; Barnes PJ
    Br J Pharmacol; 2000 Jul; 130(6):1353-61. PubMed ID: 10903976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel anti-cytokine 1,2,4-triazine derivatives.
    Khoshneviszadeh M; Ghahremani MH; Foroumadi A; Miri R; Firuzi O; Madadkar-Sobhani A; Edraki N; Parsa M; Shafiee A
    Bioorg Med Chem; 2013 Nov; 21(21):6708-17. PubMed ID: 23993677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
    Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
    J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.